89
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future

      review-article
      1 , 2 , 3 , 4 , 5 , 6 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 15 , 17 , 15 , 18 , 18 , 19 , 20 , 21 , 22 , 22 , 22 , 22 , 22 , 22 , 22 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 28 , 29 , 30 , 31 , 32 , 32 , 33 , 33 , 33 , 34 , 35 , 36 , 3 , 4 , 3 , 4 , 3 , 4 , 4 , 37 , 38 , 38 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 10 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 65 , 38 , 59 , 66 , 67
      Frontiers in Pharmacology
      Frontiers Media S.A.
      COVID-19, Africa, prevalence, treatment, misinformation, health policy, unintended consequences, review

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The COVID-19 pandemic has already claimed considerable lives. There are major concerns in Africa due to existing high prevalence rates for both infectious and non-infectious diseases and limited resources in terms of personnel, beds and equipment. Alongside this, concerns that lockdown and other measures will have on prevention and management of other infectious diseases and non-communicable diseases (NCDs). NCDs are an increasing issue with rising morbidity and mortality rates. The World Health Organization (WHO) warns that a lack of nets and treatment could result in up to 18 million additional cases of malaria and up to 30,000 additional deaths in sub-Saharan Africa.

          Objective

          Document current prevalence and mortality rates from COVID-19 alongside economic and other measures to reduce its spread and impact across Africa. In addition, suggested ways forward among all key stakeholder groups.

          Our Approach

          Contextualise the findings from a wide range of publications including internet-based publications coupled with input from senior-level personnel.

          Ongoing Activities

          Prevalence and mortality rates are currently lower in Africa than among several Western countries and the USA. This could be due to a number of factors including early instigation of lockdown and border closures, the younger age of the population, lack of robust reporting systems and as yet unidentified genetic and other factors. Innovation is accelerating to address concerns with available equipment. There are ongoing steps to address the level of misinformation and its consequences including fines. There are also ongoing initiatives across Africa to start addressing the unintended consequences of COVID-19 activities including lockdown measures and their impact on NCDs including the likely rise in mental health disorders, exacerbated by increasing stigma associated with COVID-19. Strategies include extending prescription lengths, telemedicine and encouraging vaccination. However, these need to be accelerated to prevent increased morbidity and mortality.

          Conclusion

          There are multiple activities across Africa to reduce the spread of COVID-19 and address misinformation, which can have catastrophic consequences, assisted by the WHO and others, which appear to be working in a number of countries. Research is ongoing to clarify the unintended consequences given ongoing concerns to guide future activities. Countries are learning from each other.

          Related collections

          Most cited references273

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

          Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical Characteristics of Coronavirus Disease 2019 in China

            Abstract Background Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of the affected patients. Methods We extracted data regarding 1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China through January 29, 2020. The primary composite end point was admission to an intensive care unit (ICU), the use of mechanical ventilation, or death. Results The median age of the patients was 47 years; 41.9% of the patients were female. The primary composite end point occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Only 1.9% of the patients had a history of direct contact with wildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of Wuhan, including 31.3% who had visited the city. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). Diarrhea was uncommon (3.8%). The median incubation period was 4 days (interquartile range, 2 to 7). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with nonsevere disease and in 5 of 173 patients (2.9%) with severe disease. Lymphocytopenia was present in 83.2% of the patients on admission. Conclusions During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness. Patients often presented without fever, and many did not have abnormal radiologic findings. (Funded by the National Health Commission of China and others.)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

              Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p<0·0001), and d-dimer greater than 1 μg/mL (18·42, 2·64–128·55; p=0·0033) on admission. Median duration of viral shedding was 20·0 days (IQR 17·0–24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days. Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/559547
                URI : https://loop.frontiersin.org/people/910203
                URI : https://loop.frontiersin.org/people/910520
                URI : https://loop.frontiersin.org/people/1022711
                URI : https://loop.frontiersin.org/people/508693
                URI : https://loop.frontiersin.org/people/803520
                URI : https://loop.frontiersin.org/people/691542
                URI : https://loop.frontiersin.org/people/803442
                URI : https://loop.frontiersin.org/people/994835
                URI : https://loop.frontiersin.org/people/996721
                URI : https://loop.frontiersin.org/people/750357
                URI : https://loop.frontiersin.org/people/994831
                URI : https://loop.frontiersin.org/people/994905
                URI : https://loop.frontiersin.org/people/369080
                URI : https://loop.frontiersin.org/people/1034899
                URI : https://loop.frontiersin.org/people/594773
                URI : https://loop.frontiersin.org/people/155794
                URI : https://loop.frontiersin.org/people/980091
                URI : https://loop.frontiersin.org/people/643185
                URI : https://loop.frontiersin.org/people/1032079
                URI : https://loop.frontiersin.org/people/1054525
                URI : https://loop.frontiersin.org/people/1032295
                URI : https://loop.frontiersin.org/people/1054714
                URI : https://loop.frontiersin.org/people/600828
                URI : https://loop.frontiersin.org/people/524881
                URI : https://loop.frontiersin.org/people/1015885
                URI : https://loop.frontiersin.org/people/483591
                URI : https://loop.frontiersin.org/people/559273
                URI : https://loop.frontiersin.org/people/878434
                URI : https://loop.frontiersin.org/people/1059118
                URI : https://loop.frontiersin.org/people/1022665
                URI : https://loop.frontiersin.org/people/1043736
                URI : https://loop.frontiersin.org/people/908697
                URI : https://loop.frontiersin.org/people/1032119
                URI : https://loop.frontiersin.org/people/994828
                URI : https://loop.frontiersin.org/people/278995
                URI : https://loop.frontiersin.org/people/524280
                URI : https://loop.frontiersin.org/people/687630
                URI : https://loop.frontiersin.org/people/14310
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                11 September 2020
                2020
                11 September 2020
                : 11
                : 1205
                Affiliations
                [1] 1 Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine , Lagos, Nigeria
                [2] 2 Department of Medicine, Lagos State University Teaching Hospital , Lagos, Nigeria
                [3] 3 Department of Public Health Medicine, Steve Biko Academic Hospital and the University of Pretoria , Pretoria, South Africa
                [4] 4 WHO Collaborating Centre for Social Determinants of Health and Health in all Policies , Pretoria, South Africa
                [5] 5 Charlotte Maxeke Medical Research Cluster , Johannesburg, South Africa
                [6] 6 Healthcare Improvement Scotland , Glasgow, United Kingdom
                [7] 7 Queen Elizabeth University Hospital , Glasgow, United Kingdom
                [8] 8 University of Glasgow , Glasgow, United Kingdom
                [9] 9 Department of Surveillance and Epidemiology, Nigerian Centre for Disease Control , Abuja, Nigeria
                [10] 10 Uganda Alliance of Patients’ Organizations (UAPO) , Kampala, Uganda
                [11] 11 Institute of Orthopaedic Surgery “Banjica”, University of Belgrade , Belgrade, Serbia
                [12] 12 Department of Internal Medicine, Faculty of Medicine, University of Botswana , Gaborone, Botswana
                [13] 13 Department of Internal Medicine, University of Botswana and Department of Medicine, Princess Marina Hospital , Gaborone, Botswana
                [14] 14 Department of Biomedical Sciences, Faculty of Medicine, University of Botswana , Gaborone, Botswana
                [15] 15 Effective Basic Services (eBASE) Africa , Bamenda, Cameroon
                [16] 16 Faculty of Health and Medical Sciences, Adelaide University , Adelaide, SA, Australia
                [17] 17 Department of Public Health, University of Bamenda , Bambili, Cameroon
                [18] 18 Children's Cancer Hospital , Cairo, Egypt
                [19] 19 Pharmacology Department, Medical Division, National Research Centre , Giza, Egypt
                [20] 20 Pharmacy Department, Eswatini Medical Christian University , Mbabane, Eswatini
                [21] 21 Department of Psychology, Eswatini Medical Christian University , Mbabane, Eswatini
                [22] 22 Raleigh Fitkin Memorial Hospital , Manzini, Eswatini
                [23] 23 Pharmacy Department, Ghana Police Hospital , Accra, Ghana
                [24] 24 Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, University of Ghana , Accra, Ghana
                [25] 25 Department of Medical Pharmacology, University of Ghana Medical School , Accra, Ghana
                [26] 26 Ghana Health Service, Pharmacy Department, Keta Municipal Hospital , Keta-Dzelukope, Ghana
                [27] 27 Pharmacy Practice Department, School of Pharmacy, University of Health and Allied Sciences , Hohoe, Ghana
                [28] 28 Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi , Nairobi, Kenya
                [29] 29 Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, University of Nairobi , Nairobi, Kenya
                [30] 30 Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Westville-campus , Durban, South Africa
                [31] 31 Independent Researcher , Mafeteng, Lesotho
                [32] 32 Pharmacy Department, College of Medicine, University of Malawi , Blantyre, Malawi
                [33] 33 Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia , Windhoek, Namibia
                [34] 34 Department of Pharmacology and Therapeutics, Ekiti State University , Ado-Ekiti, Nigeria
                [35] 35 Department of Medicine, Ekiti State University Teaching Hospital , Ado-Ekiti, Nigeria
                [36] 36 Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh , Pittsburgh, PA, United States
                [37] 37 Department of Family Medicine, Steve Biko Academic Hospital and University of Pretoria , Pretoria, South Africa
                [38] 38 School of Pharmacy, Sefako Makgatho Health Sciences University , Pretoria, South Africa
                [39] 39 Department of Pharmacy, Tshilidzini Hospital , Shayandima, South Africa
                [40] 40 Eugene Marais Hospital , Pretoria, South Africa
                [41] 41 National Medicines Board, Federal Ministry of Health , Khartoum, Sudan
                [42] 42 Unaizah College of Pharmacy, Qassim University , Qassim, Saudi Arabia
                [43] 43 Faculty of Medicine, University of Khartoum , Khartoum, Sudan
                [44] 44 Community Medicine Council, SMSB , Khartoum, Sudan
                [45] 45 Department of Child Health and Paediatrics, Egerton University , Nakuru, Kenya
                [46] 46 East Africa Centre for Vaccines and Immunization (ECAVI) , Kampala, Uganda
                [47] 47 Department of Pharmacy, University of Zambia , Lusaka, Zambia
                [48] 48 Department of Medicine, University of Zimbabwe College of Health Sciences , Harare, Zimbabwe
                [49] 49 Ministry of Health and Child Care , Harare, Zimbabwe
                [50] 50 London School of Hygiene and Tropical Medicine , London, United Kingdom
                [51] 51 Biomedical Research and Training Institute , Harare, Zimbabwe
                [52] 52 Zimbabwe College of Public Health Physicians , Harare, Zimbabwe
                [53] 53 Independent Consumer Advocate , Brunswick, VIC, Australia
                [54] 54 Medicines for Africa , Johannesburg, South Africa
                [55] 55 Community Health and Information Network (CHAIN) , Kampala, Uganda
                [56] 56 Liverpool Reviews and Implementation Group, University of Liverpool , Liverpool, United Kingdom
                [57] 57 WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona , Verona, Italy
                [58] 58 Department of Nutrition and Drug Research, Faculty of Health Sciences, Jagiellonian University Medical College , Krakow, Poland
                [59] 59 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde , Glasgow, United Kingdom
                [60] 60 Department of Pharmacology, College of Pharmacy, Hawler Medical University , Erbil, Iraq
                [61] 61 Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care, University of Manchester , Manchester, United Kingdom
                [62] 62 NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester , Manchester, United Kingdom
                [63] 63 Faculty of Health and Life Sciences, University of Liverpool , Liverpool, United Kingdom
                [64] 64 HCD Economics, The Innovation Centre , Daresbury, United Kingdom
                [65] 65 Pharmaceutical Administration & PharmacoEconomics, Hanoi University of Pharmacy , Hanoi, Vietnam
                [66] 66 Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge , Stockholm, Sweden
                [67] 67 School of Pharmaceutical Sciences, Universiti Sains Malaysia , Penang, Malaysia
                Author notes

                Edited by: Sam Salek, University of Hertfordshire, United Kingdom

                Reviewed by: Dan Kajungu, Makerere University, Uganda; Marc Henri De Longueville, UCB Pharma, Belgium

                *Correspondence: Brian Godman, brian.godman@ 123456strath.ac.uk

                This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology

                Article
                10.3389/fphar.2020.01205
                7533592
                33071775
                9d15e0df-3970-4b0d-ae26-0a67f00f3420
                Copyright © 2020 Ogunleye, Basu, Mueller, Sneddon, Seaton, Yinka-Ogunleye, Wamboga, Miljković, Mwita, Rwegerera, Massele, Patrick, Niba, Nsaikila, Rashed, Hussein, Hegazy, Amu, Boahen-Boaten, Matsebula, Gwebu, Chirigo, Mkhabela, Dlamini, Sithole, Malaza, Dlamini, Afriyie, Asare, Amponsah, Sefah, Oluka, Guantai, Opanga, Sarele, Mafisa, Chikowe, Khuluza, Kibuule, Kalemeera, Mubita, Fadare, Sibomana, Ramokgopa, Whyte, Maimela, Hugo, Meyer, Schellack, Rampamba, Visser, Alfadl, Malik, Malande, Kalungia, Mwila, Zaranyika, Chaibva, Olaru, Masuka, Wale, Hwenda, Kamoga, Hill, Barbui, Bochenek, Kurdi, Campbell, Martin, Phuong, Thanh and Godman

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 02 June 2020
                : 23 July 2020
                Page count
                Figures: 0, Tables: 3, Equations: 0, References: 521, Pages: 36, Words: 19736
                Categories
                Pharmacology
                Review

                Pharmacology & Pharmaceutical medicine
                covid-19,africa,prevalence,treatment,misinformation,health policy,unintended consequences,review

                Comments

                Comment on this article